Brief: Corcept Therapeutics Q4 EPS USD 0.26 Vs. IBES Estimate USD 0.43
Feb 26 (Reuters) - Corcept Therapeutics Q4 net income USD 30.746 million vs. IBES estimate USD 50.5 million. Q4 revenue USD 181.89 million vs. IBES estimate USD 198.7 million outlook FY revenue USD 900-950 million
Recent news on Corcept Therapeutics Incorporated
See all newsDrugmaker Corcept seeks to bar ex-judge's views in Teva antitrust case
Live Markets: US earnings forecast jumps further after key reports this week
Live Markets: Who's next for the S&P 500? The clock is ticking
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Corcept Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary